Compensation 990
OrganizationsEmployeesBoard MembersGrantsContractorsTop RankingsPricing

Stay updated on 990 organization compensation

© Civic Register LLC

Compensation 990 is an independent service that uses public IRS Form 990 filings as its source data. We clean and standardize this information, but the original filings may contain errors or omissions. Years on this site refer to the organization’s fiscal year end date on the filing.

About•Report a discrepancy•Your privacy choices
Organizations Medical Research Odylia Therapeutics Inc.

Odylia Therapeutics Inc.

Fiscal year ending 2024. Filed on October 23, 2025.

830 Glenwood Ave SE 510-323
Atlanta, Georgia 30316

Odylia Therapeutics Inc. (EIN: 82-2120760) has filed an IRS Form 990 since fiscal year 2018. In its fiscal year 2024 IRS Form 990 filing, Odylia Therapeutics Inc., a 501(c)(3) charitable organization, reported compensation for 2 out of 4 total employees. Among the employees shown here, the average compensation is $170,741. The highest compensated employee at Odylia Therapeutics Inc. is Ashley Winslow with fiscal year 2024 compensation of $225,220.

Revenue, expenses, and employee compensation

Revenue

$482,047

Expenses

$699,405

Employee compensation

$556,221
Revenue, expenses, and employee compensation over time

Reported Compensated Employees

Ashley Winslow
Ceo/Cso
$225,220
$217,891 No related comp$7,329
Jennifer Klein
MGR of Operations and PROG MGMT
$116,261
$116,261 No related compNo other comp

Benchmark Employee Compensation

Non-Employee Board Members

Brian Fenton
Board Member
Elizabeth Attias
Board Member
Greg Robinson
Board Member
Khandan Baradaran
Board Member
Matthew Pletcher
Board Member
Scott Dorfman
Board Chair

Mission Statement

ODLYIA'S MISSION IS TO FACILITATE THE RESEARCH OF GENETICS, GENETIC THERAPIES AND SAFE AND EFFECTIVE TREATMENTS THAT ADDRESS RARE AND ULTRA-ARE DISEASES, INCLUDING TO (I) RESEARCH AND DEVELOP METHODOLOGIES FOR MORE EFFECTIVE AND EFFICIENT DEVELOPMENT OF THERAPIES AND TREATMENTS OF RARE AND ULTRA-RARE DISEASES INCLUDING, BUT NOT LIMITED TO, THE CONDUCT AND OVERSIGHT OF CLINICAL TRIALS, (II) COMPILE AND DISSEMINATE SCIENTIFIC LITERATURE THAT PROMOTES AND ATTRACTS RESOURCES FOR RESEARCH AND THE DEVELOPMENT OF THERAPIES AND TREATMENTS THAT ADDRESS RARE AND ULTRA-RARE DISEASES, (III) DEVELOP BEST PRACTICES IN THE FIELD OF RESEARCH AND THE DEVELOPMENT OF TREATMENTS OF RARE AND ULTRA-RARE DISEASES AND (IV) ENGAGE IN AND CARRY ON ANY SUCH OTHER ACTIVITIES IN FURTHERANCE OF SUCH PURPOSES AS NONPROFIT CORPORATIONS ORGANIZED UNDER THE DELAWARE GENERAL CORPORATION LAW MAY CONDUCT, BUT ONLY TO THE EXTENT THAT SUCH ACTIVITIES SHALL BE PERMITTED UNDER SECTION 50L(C)(3) OF THE CODE.

Revisions to this organization profile

October 23, 2025:
2024 Odylia Therapeutics Inc. 990 filed
November 8, 2024:
2023 Odylia Therapeutics Inc. 990 filed
November 2, 2023:
2022 Odylia Therapeutics Inc. 990 filed

Get an email when new compensation information is released for Odylia Therapeutics Inc.

Be the first to know when new IRS Form 990 data is published for this organization.

Related Jobs

View more jobs
Powered by Talroo
Report a discrepancy →